secwatch.observer — SEC 8-K summary
======================================

Issuer:     Allarity Therapeutics, Inc. (ALLR)
CIK:        0001860657
Form:       8-K
Filed at:   2025-03-14T23:59:59+00:00
Accession:  0001437749-25-007620
Event type: regulatory
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Allarity settles SEC probe over FDA disclosures; pays $2.5M civil penalty
-------------------------------------------------------------------------

- Final settlement with SEC: administrative cease-and-desist order, no admission or denial of findings.
- Civil penalty of $2.5 million; cash runway into 2026 unchanged per prior guidance.
- Resolves investigation into past disclosures about FDA interactions regarding Dovitinib NDA (2021).
- All outstanding legal matters now concluded, including securities class action dismissed Feb 2025.
- Company reaffirms focus on stenoparib Phase 2 trials in ovarian and small cell lung cancer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1860657/000143774925007620/0001437749-25-007620-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1860657/000143774925007620/allr20250313_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-007620

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer